Swiss recommendations for the diagnosis, management and follow-up of post-COVID condition in primary care medicine (2023)

Mayssan Nehme; Lara Diem; Claudio L. A. Bassetti; Idris Guessous

doi:10.57187/s.3468

Viewpoint

Vol. 153 No. 9 (2023)

Swiss recommendations for the diagnosis, management and follow-up of post-COVID condition in primary care medicine (2023)

Mayssan Nehme
Lara Diem
Claudio L. A. Bassetti
Idris Guessous

DOI: https://doi.org/10.57187/s.3468
Cite this as:: Swiss Med Wkly. 2023;153:3468
Published: 18.09.2023

Summary

No abstract available.

References

World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. Last updated October 6, 2021 https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf [Access October 10, 2021].
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133–46. 10.1038/s41579-022-00846-2 DOI: https://doi.org/10.1038/s41579-022-00846-2
Bundesamt für Gesundheit: Coronavirus: Situation Schweiz; [Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html
Stefano GB. Historical Insight into Infections and Disorders Associated with Neurological and Psychiatric Sequelae Similar to Long COVID. Med Sci Monit. 2021 Feb;27:e931447. 10.12659/MSM.931447 DOI: https://doi.org/10.12659/MSM.931447
Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes [Erratum in: Nat Med. 2022 Aug;28] [8] [:1723. PMID: 35585196]. Nat Med. 2022 May;28(5):911–23. 10.1038/s41591-022-01810-6 DOI: https://doi.org/10.1038/s41591-022-01810-6
Nehme M, Ducrot A, Salmon D, Guessous I. Post-Covid: nouveautés 2022 et prochaines étapes [Post-Covid: 2022 updates and next steps.]. Rev Med Suisse. 2023 Feb 1;19(812):160-166. French. doi: 10.53738/REVMED.2023.19.812.160. PMID: 36723639. DOI: https://doi.org/10.53738/REVMED.2023.19.812.160
Nehme M, Vetter P, Chappuis F, Kaiser L, Covicare Study Team, Guessous I. Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status [in publication].
Corinne C. MediX long COVID recommendations https://www.medix.ch/wissen/guidelines/long-covid-factsheet/ [Last updated April 2023].
Nehme M, Braillard O, Chappuis F, Covicare study team, Guessous I. The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization. Scientific Reports [Accepted, in publication].
Centers for Disease Control and Prevention. Post-exertional malaise (PEM) [Available from: https://www.cdc.gov/me-cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html
Bach K. New data shows long Covid is keeping as many as 4 million people out of work. Brookings Institute. Aug 24, 2022.
Hôpitaux Universitaires de Genève. Prise en charge des patients souffrant de séquelles à long terme d’une infection au SARS-CoV-2. Fevrier 2021 - mise à jour Novembre 2021 https://www.hug.ch/sites/interhug/files/structures/coronavirus/guidelines-postcovid-29112021.pdf
Bassetti CL, Helbok R, Adorjan K, Falkai P. European Psychiatric Association-European Academy of Neurology statement on post-COVID syndrome. Eur J Neurol. 2023 Jan;30(1):294–5. 10.1111/ene.15572 DOI: https://doi.org/10.1111/ene.15572
Beghi E, Helbok R, Crean M, Chou SH, McNett M, Moro E, et al.; EAN Neuro-COVID Task Force. The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19. Eur J Neurol. 2021 Oct;28(10):3303–23. 10.1111/ene.14652 DOI: https://doi.org/10.1111/ene.14652
Clinicaltrials.gov NCT05497089 trial. Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome https://clinicaltrials.gov/ct2/show/NCT05497089 [Last accessed January 20, 2023].
Clinicaltrials.gov NCT05118711 Sequelae of COVID-19 With Focus on Exercise Capacity and Underlying Mechanisms (COR-PHYS) https://clinicaltrials.gov/study/NCT05118711 [Last accessed July 11, 2023].
Clinicaltrials.gov NCT05890534 Pycnogenol® in Post-COVID-19 Condition (PYCNOVID) https://classic.clinicaltrials.gov/ct2/show/NCT05890534 [Last accessed July 11, 2023].
Ducrot A, Nehme M, Sum Yu W. RAFAEL team, Schneider F, Posday-Barbe K, Guessous I. Summary of clinical trials for post-COVID condition https://www.rafael-postcovid.ch/sites/default/files/inline-files/ClinicalTrials-Version%20professionnels.pdf

CDC / Alissa Eckert, MSMI; Dan Higgins, MAMS

How to Cite

1.

Nehme M, Diem L, Bassetti CLA, Guessous I. Swiss recommendations for the diagnosis, management and follow-up of post-COVID condition in primary care medicine (2023). Swiss Med Wkly [Internet]. 2023 Sep. 18 [cited 2024 May 16];153(9):3468 . Available from: https://smw.ch/index.php/smw/article/view/3468

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

Hélène Baysson, Nick Pullen, Carlos de Mestral, Claire Semaani, Francesco Pennacchio, María-Eugenia Zaballa, Arnaud G. L’Huillier, Elsa Lorthe, Idris Guessous, Silvia Stringhini, the Specchio-COVID19 study group, Parental willingness to have children vaccinated against COVID-19 in Geneva, Switzerland: a cross-sectional population-based study , Swiss Medical Weekly: Vol. 153 No. 4 (2023)
Albina Nowak, Anne Angelillo-Scherrer, Daniel Betticher, Michael Dickenmann, Idris Guessous, Pascal Juillerat, Wolfgang Korte, Stefan Neuner-Jehle, Otmar Pfister, Daniel Surbek, Edouard Battegay, Johann Steurer, Swiss Delphi study on iron deficiency , Swiss Medical Weekly: Vol. 149 No. 2728 (2019)
Valentina Forni Ogna, Adam Ogna, Belen Ponte, Luca Gabutti, Isabelle Binet, David Conen, Paul Erne, Augusto Gallino, Idris Guessous, Daniel Hayoz, Franco Muggli, Fred Paccaud, Antoinette Péchère-Bertchi, Paolo M. Suter, Murielle Bochud, Michel Burnier, Prevalence and determinants of chronic kidney disease in the Swiss population , Swiss Medical Weekly: Vol. 146 No. 1718 (2016)
Nicolas Glatz, Aline Chappuis, David Conen, Paul Erne, Antoinette Péchère-Bertschi, Idris Guessous, Valentina Forni, Luca Gabutti, Franco Muggli, Augusto Gallino, Daniel Hayoz, Isabelle Binet, Paolo Suter, Fred Paccaud, Murielle Bochud, Michel Burnier, Swiss Medical Weekly, Associations of sodium, potassium and protein intake with blood pressure and hypertension in Switzerland , Swiss Medical Weekly: Vol. 147 No. 0708 (2017)
Idris Guessous, Murielle Bochud, Reply to the letter to the editor “Vitamin D deficiency and cardiovascular disease” by Ahmed et al. http://www.smw.ch/content/smw-2013-13821 , Swiss Medical Weekly: Vol. 143 No. 3132 (2013)
Ania Wisniak, Hélène Baysson, Nick Pullen, Mayssam Nehme, Francesco Pennacchio, María-Eugenia Zaballa, Idris Guessous, Silvia Stringhini, COVID-19 vaccination acceptance in the canton of Geneva: a cross-sectional population-based study , Swiss Medical Weekly: Vol. 151 No. 4950 (2021)
Roxane Dumont, Elsa Lorthe , Viviane Richard , Andrea Loizeau , Guillaume Fernandez , David De Ridder , Francesco Pennacchio , Julien Lamour , María-Eugenia Zaballa , Helene Baysson, Klara M. Posfay-Barbe , Remy P. Barbe, Silvia Stringhini , Idris Guessous, Prevalence of and risk factors for suicidal ideation in adolescents during the COVID-19 pandemic: a cross-sectional study , Swiss Medical Weekly: Vol. 154 No. 4 (2024)
Idris Guessous, Vincent Dudler, Nicolas Glatz, Jean-Marc Theler, Otmar Zoller, Fred Paccaud, Michel Burnier, Murielle Bochud, Vitamin D levels and associated factors: a population-based study in Switzerland , Swiss Medical Weekly: Vol. 142 No. 4748 (2012)
Antoine Flahault, Antoine Geissbuhler, Idris Guessous, Philippe J Guérin, Isabelle Bolon, Marcel Salathé, Gérard Escher, Precision global health in the digital age , Swiss Medical Weekly: Vol. 147 No. 1314 (2017)
Mayssam Nehme, Olivia Braillard, Pierre-Yves Rodondi, Idris Guessous, Use of complementary medicine and its association with SARS-CoV-2 vaccination during the COVID-19 pandemic: a longitudinal cohort study , Swiss Medical Weekly: Vol. 153 No. 12 (2023)

1 2 > >>

[1] World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. Last updated October 6, 2021 https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf [Access October 10, 2021].

[2] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133–46. 10.1038/s41579-022-00846-2 DOI: https://doi.org/10.1038/s41579-022-00846-2

[3] Bundesamt für Gesundheit: Coronavirus: Situation Schweiz; [Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html

[4] Stefano GB. Historical Insight into Infections and Disorders Associated with Neurological and Psychiatric Sequelae Similar to Long COVID. Med Sci Monit. 2021 Feb;27:e931447. 10.12659/MSM.931447 DOI: https://doi.org/10.12659/MSM.931447

[5] Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes [Erratum in: Nat Med. 2022 Aug;28] [8] [:1723. PMID: 35585196]. Nat Med. 2022 May;28(5):911–23. 10.1038/s41591-022-01810-6 DOI: https://doi.org/10.1038/s41591-022-01810-6

[6] Nehme M, Ducrot A, Salmon D, Guessous I. Post-Covid: nouveautés 2022 et prochaines étapes [Post-Covid: 2022 updates and next steps.]. Rev Med Suisse. 2023 Feb 1;19(812):160-166. French. doi: 10.53738/REVMED.2023.19.812.160. PMID: 36723639. DOI: https://doi.org/10.53738/REVMED.2023.19.812.160

[7] Nehme M, Vetter P, Chappuis F, Kaiser L, Covicare Study Team, Guessous I. Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status [in publication].

[8] Corinne C. MediX long COVID recommendations https://www.medix.ch/wissen/guidelines/long-covid-factsheet/ [Last updated April 2023].

[9] Nehme M, Braillard O, Chappuis F, Covicare study team, Guessous I. The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization. Scientific Reports [Accepted, in publication].

[10] Centers for Disease Control and Prevention. Post-exertional malaise (PEM) [Available from: https://www.cdc.gov/me-cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html

[11] Bach K. New data shows long Covid is keeping as many as 4 million people out of work. Brookings Institute. Aug 24, 2022.

[12] Hôpitaux Universitaires de Genève. Prise en charge des patients souffrant de séquelles à long terme d’une infection au SARS-CoV-2. Fevrier 2021 - mise à jour Novembre 2021 https://www.hug.ch/sites/interhug/files/structures/coronavirus/guidelines-postcovid-29112021.pdf

[13] Bassetti CL, Helbok R, Adorjan K, Falkai P. European Psychiatric Association-European Academy of Neurology statement on post-COVID syndrome. Eur J Neurol. 2023 Jan;30(1):294–5. 10.1111/ene.15572 DOI: https://doi.org/10.1111/ene.15572

[14] Beghi E, Helbok R, Crean M, Chou SH, McNett M, Moro E, et al.; EAN Neuro-COVID Task Force. The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19. Eur J Neurol. 2021 Oct;28(10):3303–23. 10.1111/ene.14652 DOI: https://doi.org/10.1111/ene.14652

[15] Clinicaltrials.gov NCT05497089 trial. Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome https://clinicaltrials.gov/ct2/show/NCT05497089 [Last accessed January 20, 2023].

[16] Clinicaltrials.gov NCT05118711 Sequelae of COVID-19 With Focus on Exercise Capacity and Underlying Mechanisms (COR-PHYS) https://clinicaltrials.gov/study/NCT05118711 [Last accessed July 11, 2023].

[17] Clinicaltrials.gov NCT05890534 Pycnogenol® in Post-COVID-19 Condition (PYCNOVID) https://classic.clinicaltrials.gov/ct2/show/NCT05890534 [Last accessed July 11, 2023].

[18] Ducrot A, Nehme M, Sum Yu W. RAFAEL team, Schneider F, Posday-Barbe K, Guessous I. Summary of clinical trials for post-COVID condition https://www.rafael-postcovid.ch/sites/default/files/inline-files/ClinicalTrials-Version%20professionnels.pdf